Innate Pharma S.A. (IPHYF)
USD 1.45
(-30.62%)
USD 1.45
(-30.62%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -4.12 Million EUR | -103.61% |
| 2022 | -2.02 Million EUR | 94.2% |
| 2021 | -34.89 Million EUR | -164.87% |
| 2020 | 53.79 Million EUR | 125.87% |
| 2019 | 23.81 Million EUR | 130.39% |
| 2018 | 10.33 Million EUR | 130.08% |
| 2017 | -34.36 Million EUR | -556.31% |
| 2016 | 7.53 Million EUR | 162.77% |
| 2015 | -12 Million EUR | -7.33% |
| 2014 | -11.18 Million EUR | -328.63% |
| 2013 | 4.89 Million EUR | 39.16% |
| 2012 | 3.51 Million EUR | -65.21% |
| 2011 | 10.1 Million EUR | 1031.24% |
| 2010 | 893 Thousand EUR | -79.56% |
| 2009 | 4.36 Million EUR | -57.85% |
| 2008 | 10.36 Million EUR | -10.05% |
| 2007 | 11.52 Million EUR | 188.53% |
| 2006 | 3.99 Million EUR | 1021.91% |
| 2005 | 356 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -8.36 Million EUR | 0.0% |
| 2024 Q1 | -8.36 Million EUR | -435.22% |
| 2023 Q2 | 19.61 Million EUR | 348.66% |
| 2023 Q3 | -1.56 Million EUR | -107.97% |
| 2023 Q4 | -1.56 Million EUR | 0.0% |
| 2023 FY | -4.12 Million EUR | -103.61% |
| 2023 Q1 | 4.37 Million EUR | 186.68% |
| 2022 FY | -2.02 Million EUR | 94.2% |
| 2022 Q2 | 28.79 Million EUR | 179.1% |
| 2022 Q1 | 10.31 Million EUR | 202.09% |
| 2022 Q4 | -5.04 Million EUR | 31.0% |
| 2022 Q3 | -7.31 Million EUR | -125.39% |
| 2021 Q2 | -1.28 Million EUR | 67.45% |
| 2021 Q3 | -7.2 Million EUR | -460.51% |
| 2021 Q4 | -10.1 Million EUR | -40.3% |
| 2021 FY | -34.89 Million EUR | -164.87% |
| 2021 Q1 | -3.94 Million EUR | -117.67% |
| 2020 Q4 | 22.34 Million EUR | 577.79% |
| 2020 Q1 | 2.62 Million EUR | -78.51% |
| 2020 Q2 | 14.09 Million EUR | 437.23% |
| 2020 Q3 | 3.29 Million EUR | -76.61% |
| 2020 FY | 53.79 Million EUR | 125.87% |
| 2019 Q2 | 33.29 Million EUR | 195.03% |
| 2019 Q1 | 11.28 Million EUR | -33.07% |
| 2019 Q3 | -7.8 Million EUR | -123.43% |
| 2019 Q4 | 12.2 Million EUR | 256.44% |
| 2019 FY | 23.81 Million EUR | 130.39% |
| 2018 Q2 | -4.66 Million EUR | 0.0% |
| 2018 FY | 10.33 Million EUR | 130.08% |
| 2018 Q1 | -4.66 Million EUR | 26.32% |
| 2018 Q4 | 16.86 Million EUR | 0.0% |
| 2018 Q3 | 16.86 Million EUR | 461.6% |
| 2017 Q2 | -5.15 Million EUR | 0.0% |
| 2017 FY | -34.36 Million EUR | -556.31% |
| 2017 Q4 | -6.32 Million EUR | 0.0% |
| 2017 Q3 | -6.32 Million EUR | -22.79% |
| 2017 Q1 | -5.15 Million EUR | -161.8% |
| 2016 FY | 7.53 Million EUR | 162.77% |
| 2016 Q1 | 206 Thousand EUR | -87.7% |
| 2016 Q2 | 206 Thousand EUR | 0.0% |
| 2016 Q3 | 8.34 Million EUR | 3948.79% |
| 2016 Q4 | 8.34 Million EUR | 0.0% |
| 2015 FY | -12 Million EUR | -7.33% |
| 2015 Q4 | 1.67 Million EUR | 0.0% |
| 2015 Q3 | 1.67 Million EUR | 141.27% |
| 2015 Q2 | -4.05 Million EUR | 0.0% |
| 2015 Q1 | -4.05 Million EUR | 25.97% |
| 2014 Q1 | -2.04 Million EUR | -197.64% |
| 2014 FY | -11.18 Million EUR | -328.63% |
| 2014 Q4 | -5.48 Million EUR | 0.0% |
| 2014 Q3 | -5.48 Million EUR | -168.19% |
| 2014 Q2 | -2.04 Million EUR | 0.0% |
| 2013 Q4 | 2.09 Million EUR | 0.0% |
| 2013 Q3 | 2.09 Million EUR | 136.9% |
| 2013 Q1 | 883.5 Thousand EUR | -33.67% |
| 2013 FY | 4.89 Million EUR | 39.16% |
| 2013 Q2 | 883.5 Thousand EUR | 0.0% |
| 2012 Q3 | 1.33 Million EUR | 0.0% |
| 2012 Q4 | 1.33 Million EUR | 0.0% |
| 2012 FY | 3.51 Million EUR | -65.21% |
| 2011 FY | 10.1 Million EUR | 1031.24% |
| 2010 FY | 893 Thousand EUR | -79.56% |
| 2009 FY | 4.36 Million EUR | -57.85% |
| 2008 FY | 10.36 Million EUR | -10.05% |
| 2007 FY | 11.52 Million EUR | 188.53% |
| 2006 FY | 3.99 Million EUR | 1021.91% |
| 2005 FY | 356 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | 142.878% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -3216.674% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 103.46% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -1189.8% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 126.717% |
| CSL Limited | 7.56 Billion USD | 100.055% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 135.204% |
| Arch Therapeutics, Inc. | -2439.00 USD | -168862.69% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 2434.051% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 84.026% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -8439.34% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 3033.096% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 127.475% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 132949.774% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 142.077% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 6369.778% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -11967.35% |
| Mesoblast Limited | -35.16 Million USD | 88.282% |
| Marizyme, Inc. | 457.7 Thousand USD | 1000.367% |
| Genus plc | 178.7 Million USD | 102.306% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 101.872% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 6722.634% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 1104.718% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -37363.636% |
| ContraFect Corporation | -154 Thousand USD | -2575.974% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -8142.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 5468.612% |
| IMV Inc. | -962.29 Thousand USD | -328.246% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -963.481% |
| MultiCell Technologies, Inc. | 49.32 USD | 8355736.659% |
| ONE Bio Corp. | 20.12 Million USD | 120.477% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 110.235% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 8527.403% |
| Q BioMed Inc. | -8988.00 USD | -45750.022% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 114.585% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -26618.102% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 109.29% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -260.993% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 5987.143% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -83118.901% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -4126.017% |
| GB Sciences, Inc. | -624.00 USD | -660316.667% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -4690.301% |
| HST Global, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -1981150.0% |
| Enzolytics Inc. | 30.7 Thousand USD | 13519.956% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 954.212% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.372% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -700.956% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 767.494% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 101.006% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -46433.424% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -4814.787% |
| Kadimastem Ltd | -630.13 Thousand USD | -553.984% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 517.113% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -34720.448% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 2434.051% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 403.653% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -14110.345% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 1015.69% |
| SYBLEU INC | 11.69 Thousand USD | 35334.268% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 189.431% |
| Bioxytran, Inc. | -8285.00 USD | -49640.495% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -1004.826% |
| Neutra Corp. | 14.33 Thousand USD | 28847.82% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -4925.61% |
| PureTech Health plc | -1.6 Million USD | -157.08% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -311.591% |
| IXICO plc | 3.27 Million USD | 226.024% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -493.804% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -130.095% |
| CSL Limited | 7.7 Billion USD | 100.053% |
| Cellectis S.A. | 18 Thousand USD | 22994.444% |